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Introduction

One of the most encouraging trends in oncology over the past
25 years has been the improvement in patient survival rates.
While this phenomenon can be attributed to the development and clinical application of a number of novel therapeutic agents, the overall impact of supportive care measures in
reducing cancer-related morbidity, and possibly even mortality,
should not be underestimated.1 The latter belief is supported,
in part, by a better understanding of the complex molecular
and biochemical pathways that regulate treatment-associated
adverse effects. For example, recognition of the 5-HT3 and
NK1 receptor pathways in nausea and vomiting as well as
identification of key proteins that regulate granulopoiesis led
to the development of agents, which continues to have a substantial impact on clinical oncology.2 However, highlighting
some of these notable achievements also exposes one glaring
deficiency – the inability to prevent, or even attenuate, cancer
treatment-induced neuropathy.
The relevance of this toxicity is further accentuated by
the observation that, in some instances, effective therapy must
be aborted, not because of drug resistance or disease progression, but rather the negative impact of neurotoxicity on the
patient’s quality of life.3 The numerous mechanisms purportedly involved in the genesis of the neuronal toxicity are also
important. The list includes, but may not be limited to, the
toxic effects on dorsal root ganglia and mitochondria, altered

neuronal blood supply, interference of axonal ion channels,
and production of reactive oxygen species and inflammatory
cytokines.4–8 Notwithstanding reports that neuroprotection
could be achieved in the laboratory by targeting or abolishing a
number of neurodegenerative events or modulating the balance
of critical proteins, clinical trials have not produced conclusive evidence to validate any preventive strategy. Indeed, the
ongoing uncertainty regarding the precise pathophysiology of
cancer treatment-induced neuropathy has impeded the deve
lopment of at least one clinically effective protective measure.
Despite the likelihood that different mechanisms exist
for different classes of anticancer agents, a unifying concept
is proposed in linking treatment-induced neurotoxicity with
disruption of microtubule function. As such, this article was
sequenced to provide the reader with: (1) a detailed primer of
the physiology and dynamics of the microtubule, (2) an abbreviated primer of the beneficial (antitumor) and detrimental
(neurotoxic) effects associated with inhibition of this complex
polymer, and (3) a scientific rationale for a proof-of-concept
clinical study.
As such, numerous publications, many old but of enduring scientific merit, as well as other, more recently, published
data were retrieved and extensively evaluated. While portions
of the published literature were used to support the accuracy
of the textual content, unresolved issues provided the opportunity for reasoned author opinions.
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Microtubule-Organizing Center

The centrosome is an intracellular entity, unique in that the
organelle is not defined by a distinct membranous boundary. Incorporated within the centrosome are two centrioles,
unusual because nine triplet microtubule units form two structurally symmetrical cylinders (Fig. 1). The centrioles, linked by
fiber-like appendages and surrounded by pericentriolar material, are comprised most notably of proteinaceous substances.
However, the proteins are not of centrosomal origin exclusively
but derive also from a labile pool in the cell cytoplasm. Access
to this bicompartmentalized source of protein is facilitated by
the lack of a clear demarcation between the centrosome and
cytoplasm. Of the numerous proteins, the gamma (γ)-tubulin
ring complex is among the most well-described components
of the pericentriolar material. The importance of this protein
is discussed later.
One of the most important activities that occur within
the centrosome is nucleation and organization of the micro
tubules. This centrosomal activity is a manifestation of both the
pericentriolar content (which contains the requisite materials)

and the centriole (which functions as the assembly platform for
microtubule formation). The requisite structural elements of
the microtubule are heterodimers of α- and β-tubulin (Fig. 2).
Interestingly, while the two protein subunits exhibit less than
50% amino acid homology, three-dimensional diffraction
studies describe crystal structures that are strikingly similar
with regard to their electron density.9 Formation of the tubulin
heterodimers is an equally delicate process that requires additional proteins (ie, chaperones and other cofactors) that assist
and provide conformational integrity related to dimer folding
and unfolding, dimer interface, and polymerization.10,11 Proto
filaments are formed by a unique sequence of events involving heterodimer elongation. Because lengthening occurs with
polar opposite α-tubulin linked to β-tubulin, the developing
asymmetrical construct engenders the exposed ends that are
negative and positive, respectively. In addition, the redundancy
of the heterodimeric structure is superficially, though erroneously, simplistic. Not overt is that only guanosine triphosphate
bound to β-tubulin is hydrolyzed, despite the presence, and
binding, of the purine nucleoside to both tubulin subunits. The

Microtubules

Fiber links centrioles

“Daughter” centriole

“Mother” centriole

Figure 1. The centrosome. Components include two centrioles of which the more mature is designated mother. Cylindrical in nature, the centriole actually
consists of nine triplet microtubular structures surrounded by pericentriolar material. The centrosome is responsible for nucleation of microtubules.

28

Clinical Medicine Insights: Oncology 2016:10

Cancer treatment-induced neuropathy
“−”

1

2

3

α-tubulin
Chaperones

MAPs

co-factors
β-tubulin

“+”

4

5

Figure 2. Basic structure of the microtubule. (1 and 2) Heterodimeric folding of α- and β-tubulin occur in the presence of molecular chaperones.
(3) MAPs facilitate tubulin dimer elongation. (4) γ-tubulin (depicted by the hook-like appendage provides directional guidance for microtubule
polymerization. Alternating rows of α (−) and β (+) heterodimers result in a structure with defined polarity. (5) Growth of the microtubule occurs
preferentially at the plus end. Random transgressions between lengthening and shortening distinguish a utilitarian behavior known as dynamic instability.

subtle implication of this finding relates to polymer formation,
which is believed to occur at the hydrolytic end.
The terminus where α-tubulin is exposed is relatively quiescent, a diskinetic state that is believed to be a consequence
of firm inter-protofilament bonding.12 The practicality of this
utilitarian conformation is supported by electron density mapping, which shows variable changes in microtubule length.13
While the stochastic shifts between lengthening and shortening, the cardinal feature known as dynamic instability, occur
primarily at the positive end, a reactive transitional state has
also been observed. The presence of this intermediary phase
appears to debunk the maxim that random shifting occurs
exclusively at the β-tubulin end.14 Indeed, additional evidence
demonstrated that severance of the β-tubulin end resulted,
as expected, in rapid microtubule shrinkage (catastrophe) in
the same vicinity. Surprisingly, restoration of growth (rescue)
began shortly after ionizing radiation-induced injury to the
α-tubulin end.

Efficacy of Conventional Antimicrotubule Agents

The tenet that inhibition of microtubule function would have
important ramifications in oncology is strongly supported
by different classes of antimicrotubule agents available for
clinical use. Despite chemical and structural differences,
the primary mechanism of their antitumor effect is believed
to be mediated by either stabilizing or destabilizing micro
tubule function.
Microtubule-stabilizing agents. Laboratory investigation indicates that the taxanes mediate their antitumor
activity primarily by blocking microtubule disassembly, thus
kinetically stabilizing the polymer. What can be perceived
as a rather soft effect is deceiving because crucial cell activities (and cell survival) depend on the unsullied dynamics
and function of the microtubule. Seemingly consistent

with this mellow disturbance is the finding that the mass
spectrum of the microtubule is unaltered. Important also,
the stabilizing agents inhibit tumor growth and survival
by sequencing two critical events. Initially, drug binding
to β-tubulin interrupts metaphase to anaphase transitioning, thereby interfering with the spindle pole resulting in
mitotic arrest. Subsequently, impairment of spindle apparatus activates (by uncertain mechanisms) multiple programed cell death pathways including the caspases and Bcl-2
family proteins.15–17
The taxanes purportedly bind to a taxoid site, which
resides behind the M-loop on the luminal surface of β-tubulin
(Fig. 3).9–12 Even though this specific locus was believed to
be the primary binding site, subsequent studies suggested
that taxane binding consisted of a two-site mechanism. Computational molecular modeling with nuclear magnetic resonance showed that binding initially involved an external pore
type-1 site followed by sequestration onto the luminal taxoid
site.18 Despite these findings, the dual-site mechanism still
remains a hypothesis.
Nascent binding notwithstanding the taxane–microtubule
interaction is a very complex phenomenon. Previously, the
binding interface of these agents was believed to involve the
M-loop and the H1-S2 loop of adjacent β-tubulin monomers,
thus increasing the lateral interactions between protofilaments.12 Other investigators localized taxane binding to a site
central to helices H1, H6, H7, and the B7-H9 on the M-loop.19
However, in later studies, it was observed that displacement
of the M-loop away from H6 in the β-monomer allosterically facilitated drug interaction with the H1-S2 loop. 20 More
recently, two studies also showed that the initial M-loop interaction promoted the curved-to-straight conformational change
that occurs with tubulin incorporation into microtubules. 21,22
Nonetheless, while the binding docket for the taxanes resides
Clinical Medicine Insights: Oncology 2016:10
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Figure 3. One-dimensional representation of tubulin heterodimer with
taxane-binding site on β-tubulin. Even though the α and β subunits
share high-sequence homology and common topology, taxane binding is
believed to be localized to the center of helices H1-S2 loop, H6, and the
B7-H9 of the M-loop.

on β-tubulin, precise mapping of the interactive site is still not
fully agreed upon.
Microtubule-destabilizing agents. Drugs such as
vincristine and vinblastine exhibit high-affinity binding
to a different, though not necessarily uniquely named, site
known as the “vinca domain,” which has been localized to
β-tubulin. 23 Drug-tubulin or drug-polymer binding disrupts polymerization or induces structural depolymerization, resulting in functional impairment of microtubule
dynamics. Notably, the vinca alkaloids can have a negative
effect on either process depending on drug concentration.
For example, it has been shown that dynamic instability of
cells in mediums containing low (ie, nanomolar) concentrations of vinblastine was effectively disrupted by increasing
the duration of the resting or pause interval; at 3-log higher
drug concentrations, microtubules depolymerized. 24 Of
note also, the vinca alkaloids appear to have concentrationdependent effects on polymer mass. At high concentrations,
these agents decrease microtubule mass by inhibiting poly
merization; at low concentrations, the vinca alkaloids interfere with microtubule dynamics without appreciably affecting
the polymer size. 25 Propagation of microtubule chaos results
in mitotic arrest between the metaphase and anaphase
transition points.
30
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Neurotoxicity Associated with Conventional
Antimicrotubule Agents

Despite what is arguably their target, the microtubule inhibitors are not considered to be true targeting agents as is currently defined. As such, cell damage associated with these
drugs is not restricted to the tumor but includes cells of many
other (normal) tissues. One major aspect of bystander damage
common to all agents that alter microtubule function involves
neuronal tissue. While the severity of neuropathy usually
varies with duration of therapy, neurotoxicity is the most frequent treatment-limiting adverse effect of these agents. Even
though it remains unclear why the peripheral nervous system
is at particular risk, a number of alleged biological factors
have been proposed. Because of the significant clinical consequences, a critical analysis of existing data was performed to
explain the underlying mechanisms of this tactile toxicity.
The neuronal framework is structurally composed of
microtubules, neurofilaments, and microfilaments. Each of
these separate, yet interactive, polymeric elements have very
unique properties. Microtubules have a performance repertoire that includes a functional architectural role as well as
serving as a cellular causeway for trafficking proteins and
other components. These functions can be further elaborated
upon. Although α- and β-tubulin monomers are synthesized
in the cell body of the neuron, polymer formation takes place
in the distal region of growing axons. 26 The restrictive sites of
these two processes highlight what appears to be an orderly
transport of proteins, including tubulin and other micro
tubule-associated proteins (MAPs), which are essential for the
formation of the platform to support construction of the axonal
cytoskeleton.27 In essence, the integrity of the nervous system,
which relies on the directional transport of neurotransmitter
from perikaryon to synaptic cleft, is largely dependent on a
functional microtubule network.
One of the most intriguing (and perplexing) aspects of
the axonal cytoskeleton relates to the marked difference in the
regenerative ability of axons following injury between neurons
of the central and peripheral nervous systems.28 One plausible explanation for the difference was provided by investigators studying traumatically injured axons. 29 In their report,
Conde et al discovered two distinct phenomena occurring
at the damaged site. Subsequent to injury, bulbous swelling
followed by internal retraction (hence the descriptive terms
retraction bulbs) was observed in the axons of central origin.
On the other hand, equally conspicuous inclusion bodies protruded from the injured peripheral axons. Because of their
restorative effect on axonal elongation, these reactive structures were labeled growth cones.30 What may have also contributed to axonal repair were increased concentrations of
microtubules. Arguably, the appearance of the microtubules
at the damaged site could be perceived as being merely coincidental. Alternatively, it is conceivable that the large assemblage and functional repertoire of the microtubules at the
sites of axonal regrowth is consistent with the fundamental
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(and indispensable) role of the polymer in reversing growth
cone stalling and re-establishing neuronal function.31
These data provide a credible explanation for neurotoxicity
associated with microtubule dysfunction. As such, disruption
of dynamic instability interferes not only with the cytoskeletal
structure and network but also with the axonal transport and
directional conduction of electrical impulses away from the
cell body. In addition, the morbid (and usually reversible) and
mortal (and almost always fatal) consequences associated with
peripheral and, sometimes negligent, central administration
of vincristine could be explained by the appearance of growth
cones and retraction bulbs, respectively.32,33
One other important issue that needs to be addressed
relates to the relatively selective injury to the peripheral nervous system. The simplest explanation relates to the likelihood
that most of the anticancer agents, including the micro
tubule inhibitors, do not (or have negligible ability to) cross
the blood–brain barrier. 34 However, a more erudite precis’
on the topic revolves around the structural integrity of the
microtubule after drug-related or trauma-induced injury that
determines whether axons survive or die. Based on a several
ingenious in vitro and in vivo studies, researchers observed
that growth cones from injured peripheral axons exposed to
increasing concentrations of a vinca analog underwent transformation to bulb-like appendages, much like retraction
bulbs found on the damaged axons of central nervous system
origin.35 Notably, the transformed growth cones contained
conspicuously disorganized (and dysfunctional) microtubules,
features identical to the polymeric structures found in the
central neuronal retraction bulbs. Likewise, the transformed
cones were also devoid of regenerative ability. It is emphasized
that the observed transformation was dependent on drug concentration. At high concentrations, growth cones underwent
transformation in half of all the neurons compared with the
neurons exposed to the control (drug-free) medium. This finding could explain the recovery of peripheral neurotoxic reactions associated with vinca alkaloid therapy.
With a reasonable amount of certainty, the observation
that microtubule destabilization generated retraction bulbs
would translate to the intriguing possibility that stabilization
of the intact polymer should inhibit bulb formation. An ingenious study conducted to test this hypothesis involved conditioning of CNS neurons in taxane-containing or control
(saline) mediums.35 The laboratory results revealed striking differences. First, even though bulb-like appendices
developed on damaged axons bathed in both mediums, the
taxane-conditioned cells exhibited significantly fewer bulbous
elements. Second, the retraction bulbs of the taxane-treated
axons were unusually small in size compared with control.
And third, the orientation and arrangement of axonal microtubules in the smaller protuberant bodies were nearly identical
to microtubules found in growth cones. These provocative data
strongly suggest that microtubule stabilization hinders gene
ration of retraction bulbs and either impedes axonal shortening

or promotes axonal regrowth. These findings are even more
remarkable when compared with studies using neurons from
the peripheral nervous system, which showed no difference in
axonal features regardless of the conditioning media. Whereas
the collective findings infer that microtubule-stabilizing
agents may be less toxic than destabilizing agents, these data
also appear to provide insight of the molecular mechanisms
underlying the development (and reversal) of drug-induced
neurotoxicity. At the same time, it is important to stress the
role of other components, including MAPs, 36 nerve growth
factor, 37 intermediate filaments, 38 as well as other proteins,
such as actin microfilaments and plectin.39

Incidental Microtubule-Damaging Agents

Although frequently associated with drugs that stabilize or
destabilize the microtubule, significant neurotoxicity also
develops during treatment with bortezomib and oxaliplatin. Not considered traditional antimicrotubule agents, these
two drugs were included in this article because their surreptitious effects on the microtubule strengthen the belief that
the tubulin complex may be the crux of cancer treatmentassociated neurotoxicity.
Proteasome inhibitors. Bortezomib, a proteasome inhibi
tor, represents an anomaly in oncology.40 Proteasomes are
cytoplasmic and nuclear constituents of all eukaryotic cells. In
conjunction with ubiquitin, the proteasome-ubiquitin pathway
is responsible for the constitutive degradation of the majority
of cellular proteins. The apparent aberration stems from the
finding that targeted inhibition of the 26S proteasome, an
essential component of cell metabolism, retards tumor progression by interfering with the orderly degradation of normal, key regulatory molecules. In essence, this pathway plays a
pivotal role in regulating the balance between de novo protein
synthesis and proteolysis.
Indeed, the link between microtubule and proteasome is
strengthened by laboratory studies demonstrating localization
of major elements of the proteasome–ubiquitin pathway to the
centrosome in cells during interphase.41 And perhaps not surprising was the observation that inhibition of the proteasome
impinged on spindle dynamics, resulting in the fragmentation of the spindle apparatus.42 These intriguing findings led
to further studies, one of which is most galvanizing. While
it was known that various proteins (of which γ-tubulin is the
best characterized) were ensconced within the pericentriolar
material surrounding the centrioles,43 French investigators
discovered that cells treated with proteasome inhibitors accumulated large amounts of centrosomal proteins, including an
insoluble form of γ-tubulin with a higher molecular weight.44
Because microtubule nucleation is the event that initiates de
novo polymerization of α-β tubulin dimers, an important
question was to determine whether the accumulated proteins could alter the capacity of the centrosome to nucleate
microtubules. The researchers found that not only the proteasome inhibitor, PS-341 (bortezomib), impaired microtubule
Clinical Medicine Insights: Oncology 2016:10
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nucleation but the drug-treated cells also lacked a discernable
microtubule-organizing center. Notably, allowing the cells
to recover following drug removal resulted in the normalization of both processes. Still, a couple of uncertainties exist.
One relates to the functionality of insoluble γ-tubulin; and
two, the precise mechanism underlying the accumulation of
the centrosome proteins following proteasomal inhibition.
Perhaps the most plausible explanation for the latter is failure
of the proteasome to degrade poly-ubiquitylated proteins.
While the importance of proper assembly and the number
of centrosomes have been correlated with genetic instability
and human cancer, it is conceivable that deregulation of
microtubule organization could also be associated with drugrelated neurotoxicity.
In addition to the proteasome inhibitors, the platinum
compounds have had a major impact on the treatment of various malignancies. Of the latter agents, oxaliplatin has emerged
as one of the most important new cytotoxic drugs. Classified
as an alkylating agent,45 this platinum analog contains a sterically bulky ligand (1,2-diaminocyclohexane [DACH]) and a
labile oxalate ligand, which distinguish this compound from
cisplatin or carboplatin.46 Formation of site-specific DNAprotein-oxaliplatin as well as inter-DNA-platinum crosslinks
is believed to be the basis for inhibiting DNA transcription
and replication. Interestingly, although fewer in number (compared with cisplatin), the formed crosslinks are reported to be
more potent, a finding possibly related to the DACH ligand.
Platinum agents. Oxaliplatin, a third-generation platinum agent, is considered one of the two most important new
drugs used in the treatment of colorectal cancer. Despite the
clinical impact and attendant enthusiasm for this agent, the
applicability of oxaliplatin is limited, in large part, by sensory
neuropathy. Importantly, neurotoxicity, not tumor progression, is the most frequent reason that forces patients to forego
further therapy with this agent. Because the approved use of
oxaliplatin has, for the first time in over 50 years, improved
overall survival in patients with colorectal cancer, effective
prophylaxis against this toxicity should still be considered a
priority for innovative prevention research.
The biochemical mechanism of the neurotoxic reaction
was initially believed to involve voltage-gated sodium channels
through chelation of calcium by a metabolite of oxaliplatin.47
The apparent, though small, benefit of calcium/magnesium
infusions was consistent with the notion that altered calcium
homeostasis may have a role in inducing neurotoxicity.48 However, results of a definitive clinical trial showed that calcium
(and magnesium) infusions have no proven benefit against
oxaliplatin-induced neurotoxicity.49
More recently, studies in animal models strongly suggest
the role of transport mechanisms in platinum-induced neurotoxicity. Ciarimboli et al reported that accumulation of drug
in, and damage to, neuronal cells was linked to organic cation
transporter 2 (OCT2), a protein expressed in the neurons
of the dorsal root ganglia.50,51 Interestingly, overexpression
32
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of OCT2 resulted in a significant (up to 35-fold) increase
in neuronal uptake of oxaliplatin, while OCT2 gene knockout protected against the development of peripheral neurotoxicity.52 However, a potential obstacle related to targeting
OCT2 for preventive therapy is that the protein belongs to a
major facilitator superfamily of transporters, which includes
OCT1–3 (electrogenic cation transporters), OCTN1–3 (electroneutral cation transporters), and OAT1–5 (organic anion
transporters). Indeed, repression of the transporter’s direct
impact of drug uptake into neuronal cells could, simultaneously, antagonize the antitumor effect since many of these
transporters, including OCT2, are expressed in the tissues of
the gastrointestinal tract.53

Integrated Hypothesis of Oxaliplatin-Induced
Neurotoxicity

Although calcium regulation involves several organs and
hormones, vitamin D is known to be an integral component for numerous physiological functions of calcium at tissue and cellular levels. In addition to its well-known effect
on bone health, the neuromuscular system is now recognized
as another important target for the wide-ranging effects of
this hormone. A number of publications have addressed the
role of vitamin D in diseases such as multiple sclerosis and
Parkinson’s disease.54–56 Even more intriguing are laboratory
data showing the neuroprotective effects of the hormone in
laboratory models of Parkinson’s disease and amyotrophic
lateral sclerosis.57–59 However, these data are tempered by the
understanding that epidemiologic studies suggest correlation
rather than causation; while success observed in preclinical
models may not fully translate in human trials. Nonetheless,
these data do suggest that the neuromuscular system may be
another target of the pleiotropic effects of vitamin D. Hence,
these data cannot be totally eschewed. What remains as the
most relevant issue of this article is to elucidate a link between
oxaliplatin and the microtubule and generate a hypothesis to
drive a proof-of-concept clinical study.
Intuitively, any neuroprotective strategy aimed at preserving microtubule function would be irrational if both
antitumor and neurotoxic effects were invariably linked to
microtubule dysfunction. As such, effective preventive therapies for the traditional microtubule inhibitors discussed above
would be extremely challenging. However, effective prevention of neurotoxicity may be achievable if disruption of microtubule function was independent of the dominant antitumor
mechanism. Such may be the case with the platinum analogs.
Given this principle, and the vitamin’s link to calcium,
the supposition that vitamin D may be clinically beneficial
appears not only suspicious but also irrational. If so, then what
would support the apparent discordance attached to the proposed beneficial effect of vitamin D? The answer may reside
in the relationship between vitamin D and the microtubule.
As indicated previously, microtubules are relatively simple, yet
paradoxically complex, intracellular polymers. Regardless of
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manner, deregulation of the microtubule-organizing center
or the microtubule itself results in mitotic arrest, the purported mechanism of tumor cell death. However, compelling
evidence suggests that alteration of tubulin dynamics also
increases the risk of toxicity to peripheral neurons, an adverse
effect observed with all microtubule inhibitors. Even though
the factors for the increased sensitivity of neuronal tissue to
the antimicrotubule inhibitors remain elusive, a proffered
explanation was provided earlier in this article. Briefly, the
pathologic process could be described in the following manner.
While synthesis of tubulin monomers is restricted to the perikaryon, polymerization occurs distally in regions of axonal
growth.26 Limitation of these two processes emphasizes
an orderly mechanism for transporting tubulin and other
microtubule-essential proteins required for constructing the
neuronal cytoskeleton.27 Indeed, the ultimate shape of the
cytoskeleton, integrity of the intracellular protein transport
system, and function of the nervous system are dependent on
the tubulin network.
Having established a biological link between the microtubule and neurotoxicity leaves the larger, but not impossible, task of elucidating a connection between oxaliplatin,
the microtubule, and vitamin D. Even though not classified
as antimicrotubule agents, platinum compounds have been
shown to form platinum-tubulin adducts causing denatura
tion of tubulin, disruption of polymerization, and inhibition of the microtubule.60 Of particular importance was the
finding that disruption of microtubule function has been
shown to result in a marked decrease in the formation of the
active hormone, 1α,25(OH)2D3, not because of decreased
cellular uptake of 25(OH)D3, but rather altered substrate
transport. If so, then supraphysiological concentrations of
25(OH)D3 may be able to correct the defect without altering oxaliplatin’s antitumor effect. In fact, vitamin D may
have the opposite effect of increasing the antitumor effect
of oxaliplatin.61

Conclusion

Reasonably compelling evidence suggests an association that
exists between cytoskeletal and axonal function, neurotoxicity,
oxaliplatin, and vitamin D. And perhaps of equal importance is the possibility of correcting a ubiquitous irony in
clinical research. In this context, a vitamin that may modulate numerous protective effects and costs only a few pennies a
day can be considered a worthy clinical trial investment. Such
a clinical study is currently being conducted to evaluate the
validity of this hypothesis.
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